✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life.
📊
Key Findings & Data:Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life.
💡
Conclusion & Impact:This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:biyolojik · keilit · tildrakizumab
Abstract
Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
Keywords
🔖
Cite This Article
COWAN, T., ALRUB, N. A., WİLSON, A., MAKHİJA, M., MURRELL, D. (2023). Tildrakizumab for the treatment of exfoliative cheilitis. Mucosa, Cilt: 6 - Sayı: 1, 19–21. https://ajindex.com/articles/879358